Latest From Zogenix Inc.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.
EMD Serono’s multiple sclerosis drug joins small cadre of products that survived a refuse to file letter and NDA withdrawal; chart details recent RTFs and application withdrawals.
Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- SJ2 Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Zogenix Inc.
- Senior Management
Stephen J Farr, PhD, Pres. & CEO
Michael P Smith, EVP, CFO, Treasurer & Secretary
Bradley S Galer, MD, EVP, CMO
Gail M Farfel, PhD, EVP, Chief Dev. Officer
Ashish Sagrolikar, EVP, Chief Commercial Officer
- Contact Info
Phone: (858) 259-1165
5858 Horton St.
Emeryville, CA 94608
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.